BioStem Gains on Medicare National Pricing for Wound Care Product

Seeking AlphaOct 16 00:50

Express News | Biostem Technologies Inc - Trial Expected to Complete by End of 2025

BreakingsOct 2 19:00

Express News | Biostem Technologies Initiates Br-Ac-Dfu-101 Clinical Trial to Study Bioretain® in Diabetic Foot Ulcers

BreakingsOct 2 19:00

Express News | Biostem Receives Institutional Review Board (Irb) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers

BreakingsAug 21 19:00

Earnings Call Summary | BIOSTEM TECHNOLOGIES INC(BSEM.US) Q2 2024 Earnings Conference

Futu NewsAug 13 13:43 · Conference Call

BioStem Technologies GAAP EPS of $0.39 Beats by $0.27, Revenue of $74.5M Beats by $30.5M

Seeking AlphaAug 13 04:31